LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice

Journal of Lipid Research

Volumn 55, Issue 8, 2014, Pages 1721-1729

  Stukas, Sophie ^a   Freeman, Lita ^b   Lee, Michael ^a   Wilkinson, Anna ^a   Ossoli, Alice ^b   Vaisman, Boris ^b   Demosky, Stephen ^b   Chan, Jeniffer ^a   Hirsch Reinshagen, Veronica ^a   Remaley, Alan T ^b   Wellington, Cheryl L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alzheimer's disease; Apolipoproteins; High density lipoprotein metabolism; Lecithin:cholesterol acyltransferase

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; MESSENGER RNA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRESENILIN 1; AMYLOID BETA PROTEIN;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBROSPINAL FLUID; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; HIPPOCAMPUS; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPOPROTEIN METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN A-I; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; MICE; MICE, KNOCKOUT; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 84905046403     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M049940     Document Type: Article

References (58)

1. Verghese, P. B., J. M. Castellano, and D. M. Holtzman. 2011. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10: 241-252.
2. Corder, E. H., A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, and M. A. Pericak-Vance. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261: 921-923. (Pubitemid 23275809)
3. Stukas, S., J. Robert, and C. L. Wellington. 2014. High density lipoproteins and cerebrovasular integrity in Alzheimer's disease. Cell Metab. 19: 574-591.
4. Strittmatter, W. J., A. M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G. S. Salvesen, and A. D. Roses. 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90: 1977-1981. (Pubitemid 23069980)
5. Schmechel, D. E., A. M. Saunders, W. J. Strittmatter, B. J. Crain, C. M. Hulette, S. H. Joo, M. A. Pericak-Vance, D. Goldgaber, and A. D. Roses. 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90: 9649-9653. (Pubitemid 23315843)
6. Polvikoski, T., R. Sulkava, M. Haltia, K. Kainulainen, A. Vuorio, A. Verkkoniemi, L. Niinisto, P. Halonen, and K. Kontula. 1995. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med. 333: 1242-1247.
7. Holtzman, D. M., A. M. Fagan, B. Mackey, T. Tenkova, L. Sartorius, S. M. Paul, K. Bales, K. H. Ashe, M. C. Irizarry, and B. T. Hyman. 2000. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47: 739-747. (Pubitemid 30390194)
8. Irizarry, M. C., G. W. Rebeck, B. Cheung, K. Bales, S. M. Paul, D. Holzman, and B. T. Hyman. 2000. Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann. N. Y. Acad. Sci. 920: 171-178. (Pubitemid 32056566)
9. Bales, K. R., T. Verina, D. J. Cummins, Y. Du, R. C. Dodel, J. Saura, C. E. Fishman, C. A. DeLong, P. Piccardo, V. Petegnief, et al. 1999. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96: 15233-15238. (Pubitemid 30019795)
10. Bales, K. R., T. Verina, R. C. Dodel, Y. Du, L. Altstiel, M. Bender, P. Hyslop, E. M. Johnstone, S. P. Little, D. J. Cummins, et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17: 263-264.
11. Fryer, J. D., J. W. Taylor, R. B. DeMattos, K. R. Bales, S. M. Paul, M. Parsadanian, and D. M. Holtzman. 2003. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 23: 7889-7896. (Pubitemid 37052357)
12. Holtzman, D. M., K. R. Bales, T. Tenkova, A. M. Fagan, M. Parsadanian, L. J. Sartorius, B. Mackey, J. Olney, D. McKeel, D. Wozniak, et al. 2000. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97: 2892-2897. (Pubitemid 30159268)
13. Fagan, A. M., M. Watson, M. Parsadanian, K. R. Bales, S. M. Paul, and D. M. Holtzman. 2002. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9: 305-318. (Pubitemid 34442079)
14. Fryer, J. D., K. Simmons, M. Parsadanian, K. R. Bales, S. M. Paul, P. M. Sullivan, and D. M. Holtzman. 2005. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25: 2803-2810. (Pubitemid 40389238)
15. Bales, K. R., F. Liu, S. Wu, S. Lin, D. Koger, C. DeLong, J. C. Hansen, P. M. Sullivan, and S. M. Paul. 2009. Human APOE isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29: 6771-6779.
16. Castellano, J. M., J. Kim, F. R. Stewart, H. Jiang, R. B. DeMattos, B. W. Patterson, A. M. Fagan, J. C. Morris, K. G. Mawuenyega, C. Cruchaga, et al. 2011. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3: 89ra57.
17. Kim, J., H. Jiang, S. Park, A. E. Eltorai, F. R. Stewart, H. Yoon, J. M. Basak, M. B. Finn, and D. M. Holtzman. 2011. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31: 18007-18012.
18. Sagare, A. P., R. D. Bell, and B. V. Zlokovic. 2012. Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2: a011452.
19. Saido, T., and M. A. Leissring. 2012. Proteolytic degradation of amyloid β-protein. Cold Spring Harb. Perspect. Med. 2: a006379.
20. Deane, R., A. Sagare, K. Hamm, M. Parisi, S. Lane, M. B. Finn, D. M. Holtzman, and B. V. Zlokovic. 2008. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118: 4002-4013.
21. Bell, R. D., A. P. Sagare, A. E. Friedman, G. S. Bedi, D. M. Holtzman, R. Deane, and B. V. Zlokovic. 2007. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27: 909-918. (Pubitemid 46659038)
22. Bien-Ly, N., A. K. Gillespie, D. Walker, S. Y. Yoon, and Y. Huang. 2012. Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32: 4803-4811.
23. Verghese, P. B., J. M. Castellano, K. Garai, Y. Wang, H. Jiang, A. Shah, G. Bu, C. Frieden, and D. M. Holtzman. 2013. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc. Natl. Acad. Sci. USA. 110: E1807-E1816.
24. Tai, L. M., T. Bilousova, L. Jungbauer, S. K. Roeske, K. L. Youmans, C. Yu, W. W. Poon, L. B. Cornwell, C. A. Miller, H. V. Vinters, et al. 2013. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J. Biol. Chem. 288: 5914-5926.
25. Fryer, J. D., R. B. Demattos, L. M. McCormick, M. A. O'Dell, M. L. Spinner, K. R. Bales, S. M. Paul, P. M. Sullivan, M. Parsadanian, G. Bu, et al. 2005. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280: 25754-25759. (Pubitemid 40962285)
26. Castellano, J. M., R. Deane, A. J. Gottesdiener, P. B. Verghese, F. R. Stewart, T. West, A. C. Paoletti, T. R. Kasper, R. B. DeMattos, B. V. Zlokovic, et al. 2012. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc. Natl. Acad. Sci. USA. 109: 15502-15507.
27. Johnson, L. A., R. H. Olsen, L. S. Merkens, A. DeBarber, R. D. Steiner, P. M. Sullivan, N. Maeda, and J. Raber. 2014. Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner. Neurobiol. Dis. 64: 150-162.
28. Hirsch-Reinshagen, V., S. Zhou, B. L. Burgess, L. Bernier, S. A. McIsaac, J. Y. Chan, G. H. Tansley, J. S. Cohn, M. R. Hayden, and C. L. Wellington. 2004. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279: 41197-41207. (Pubitemid 39287722)
29. Wahrle, S. E., H. Jiang, M. Parsadanian, J. Legleiter, X. Han, J. D. Fryer, T. Kowalewski, and D. M. Holtzman. 2004. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279: 40987-40993. (Pubitemid 39287699)
30. Koldamova, R., N. F. Fitz, and I. Lefterov. ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol. Dis. Epub ahead of print. May 17, 2014; doi:10.1016/j.nbd.2014,05,007.
31. Aiello, R. J., D. Brees, and O. L. Francone. 2003. ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler. Thromb. Vasc. Biol. 23: 972-980. (Pubitemid 36713549)
32. Hirsch-Reinshagen, V., L. F. Maia, B. L. Burgess, J. F. Blain, K. E. Naus, S. A. McIsaac, P. F. Parkinson, J. Y. Chan, G. H. Tansley, M. R. Hayden, et al. 2005. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280: 43243-43256. (Pubitemid 43049291)
33. Koldamova, R., M. Staufenbiel, and I. Lefterov. 2005. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280: 43224-43235. (Pubitemid 43049289)
34. Wahrle, S. E., H. Jiang, M. Parsadanian, R. E. Hartman, K. R. Bales, S. M. Paul, and D. M. Holtzman. 2005. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280: 43236-43242. (Pubitemid 43049290)
35. Wahrle, S. E., H. Jiang, M. Parsadanian, J. Kim, A. Li, A. Knoten, S. Jain, V. Hirsch-Reinshagen, C. L. Wellington, K. R. Bales, et al. 2008. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118: 671-682. (Pubitemid 351206556)
36. Fan, J., S. Stukas, C. Wong, J. Chan, S. May, N. DeValle, V. Hirsch-Reinshagen, A. Wilkinson, M. N. Oda, and C. L. Wellington. 2011. An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia. J. Lipid Res. 52: 1605-1616.
37. DeMattos, R. B., R. P. Brendza, J. E. Heuser, M. Kierson, J. R. Cirrito, J. Fryer, P. M. Sullivan, A. M. Fagan, X. Han, and D. M. Holtzman. 2001. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem. Int. 39: 415-425. (Pubitemid 32907406)
38. LaDu, M. J., S. M. Gilligan, J. R. Lukens, V. G. Cabana, C. A. Reardon, L. J. Van Eldik, and D. M. Holtzman. 1998. Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 70: 2070-2081. (Pubitemid 28207831)
39. Fagan, A. M., D. M. Holtzman, G. Munson, T. Mathur, D. Schneider, L. K. Chang, G. S. Getz, C. A. Reardon, J. Lukens, J. A. Shah, et al. 1999. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J. Biol. Chem. 274: 30001-30007.
40. Pitas, R. E., J. K. Boyles, S. H. Lee, D. Hui, and K. H. Weisgraber. 1987. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262: 14352-14360. (Pubitemid 17152101)
41. Koch, S., N. Donarski, K. Goetze, M. Kreckel, H. J. Stuerenburg, C. Buhmann, and U. Beisiegel. 2001. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42: 1143-1151. (Pubitemid 32645797)
42. Demeester, N., G. Castro, C. Desrumaux, C. De Geitere, J. C. Fruchart, P. Santens, E. Mulleners, S. Engelborghs, P. P. De Deyn, J. Vandekerckhove, et al. 2000. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J. Lipid Res. 41: 963-974. (Pubitemid 30434328)
43. Rousset, X., R. Shamburek, B. Vaisman, M. Amar, and A. T. Remaley. 2011. Lecithin cholesterol acyltransferase: an anti- or proatherogenic factor? Curr. Atheroscler. Rep. 13: 249-256.
44. Ng, D. S., O. L. Francone, T. M. Forte, J. Zhang, M. Haghpassand, and E. M. Rubin. 1997. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J. Biol. Chem. 272: 15777-15781. (Pubitemid 27265554)
45. Sakai, N., B. L. Vaisman, C. A. Koch, R. F. Hoyt, Jr., S. M. Meyn, G. D. Talley, J. A. Paiz, H. B. Brewer, Jr., and S. Santamarina-Fojo. 1997. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J. Biol. Chem. 272: 7506-7510. (Pubitemid 27166465)
46. Tanigawa, H., J. T. Billheimer, J. Tohyama, I. V. Fuki, D. S. Ng, G. H. Rothblat, and D. J. Rader. 2009. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation. 120: 160-169.
47. Hirsch-Reinshagen, V., J. Donkin, S. Stukas, J. Chan, A. Wilkinson, J. Fan, J. S. Parks, J. A. Kuivenhoven, D. Lutjohann, H. Pritchard, et al. 2009. LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins. J. Lipid Res. 50: 885-893.
48. Albers, J. J., S. M. Marcovina, and R. H. Christenson. 1992. Lecithin cholesterol acyltransferase in human cerebrospinal fluid: reduced level in patients with multiple sclerosis and evidence of direct synthesis in the brain. Int. J. Clin. Lab. Res. 22: 169-172.
49. DeMattos, R. B., K. R. Bales, M. Parsadanian, M. A. O'Dell, E. M. Foss, S. M. Paul, and D. M. Holtzman. 2002. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81: 229-236. (Pubitemid 34809348)
50. Vaisman, B. L., H. G. Klein, M. Rouis, A. M. Berard, M. R. Kindt, G. D. Talley, S. M. Meyn, R. F. Hoyt, Jr., S. M. Marcovina, J. J. Albers, et al. 1995. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J. Biol. Chem. 270: 12269-12275.
51. Vaisman, B. L., and A. T. Remaley. 2013. Measurement of lecithin-cholesterol acyltransferase activity with the use of a Peptide-proteoliposome substrate. Methods Mol. Biol. 1027: 343-352.
52. Yesilaltay, A., M. G. Morales, L. Amigo, S. Zanlungo, A. Rigotti, S. L. Karackattu, M. H. Donahee, K. F. Kozarsky, and M. Krieger. 2006. Effects of hepatic expression of the high-density lipoprotein receptor SR-BI on lipoprotein metabolism and female fertility. Endocrinology. 147: 1577-1588.
53. Freeman, L. A. 2013. Western blots. Methods Mol. Biol. 1027: 369-385.
54. Han, B. H., M. L. Zhou, A. K. Vellimana, E. Milner, D. H. Kim, J. K. Greenberg, W. Chu, R. H. Mach, and G. J. Zipfel. 2011. Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol. Neurodegener. 6: 86.
55. Lefterov, I., N. F. Fitz, A. A. Cronican, A. Fogg, P. Lefterov, R. Kodali, R. Wetzel, and R. Koldamova. 2010. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J. Biol. Chem. 285: 36945-36957.
56. Calabresi, L., E. Favari, E. Moleri, M. P. Adorni, M. Pedrelli, S. Costa, W. Jessup, I. C. Gelissen, P. T. Kovanen, F. Bernini, et al. 2009. Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis. 204: 141-146.
57. Kay, A. D., S. P. Day, M. Kerr, J. A. Nicoll, C. J. Packard, and M. J. Caslake. 2003. Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury. J. Neurotrauma. 20: 717-723. (Pubitemid 36993447)
58. Namjoshi, D. R., G. Martin, J. Donkin, A. Wilkinson, S. Stukas, J. Fan, M. Carr, S. Tabarestani, K. Wuerth, R. E. Hancock, et al. 2013. The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E. PLoS ONE. 8: e53529.